Skip to main content
. 2019 May 16;10(6):385. doi: 10.1038/s41419-019-1621-2

Fig. 1. CDK1/cyclin B1 kinase complex phosphorylates SET isoform 1 in vitro.

Fig. 1

a HeLa cells were treated with DMSO (control), taxol (100 nM for 16 h), or nocodazole (Noco, 100 ng/ml for 16 h). Total cell lysates were electrophoresed on regular and Phos-tag SDS polyacrylamide gels and probed with the indicated antibodies. Increased cyclin B1 levels marks cells in mitosis. An asterisk (*) marks the phosphorylated/shifted band. b HeLa cells were treated with nocodazole as indicated and cell lysates were further treated with (+) or without (−) λ phosphatase (ppase). Total cell lysates were probed with the indicated antibodies. Increased cyclin B1 levels marks cells in mitosis. An asterisk marks the phosphorylated/shifted band. c HeLa cells were treated with nocodazole, with or without various kinase inhibitors as indicated. Inhibitors were added 1.5 h before harvesting the cells (with MG132 to prevent cyclin B degradation and subsequent mitotic exit). The concentrations used for each inhibitor were as follows: VX680 2 μM, RO3306 5 μM, Purvalanol A 10 μM, BI-2536 100 nM, SB216763 10 μM, MK-2206 10 μM, SB203580 10 μM, U0126 20 μM, SP600125 20 μM, LY294002 30 μM, and rapamycin 100 nM. Total cell lysates were electrophoresed on regular and Phos-tag SDS polyacrylamide gels and probed with the indicated antibodies. Increased cyclin B1 levels mark cells in mitosis. An asterisk marks the phosphorylated/shifted band. d In vitro kinase assays with purified CDK1/cyclin B1 complex using GST-tagged SET isoform 1 proteins as substrates. RO3306 (5 µM) was used to inhibit CDK1/cyclin B1 kinase activity. e GST-SET and GST-SET-S7A proteins were used for in vitro kinase assays with purified CDK1/cyclin B1 complex. f In vitro kinase assays were done as in e except anti-phospho-SET S7 antibody was used